Empadiance 25 is an oral antidiabetic medication containing **Empagliflozin**, a selective **SGLT2 inhibitor**, produced by Alhavi Pharmaceutical.
It is used to manage blood glucose levels in adults with type 2 diabetes mellitus by inhibiting glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and reduced blood sugar levels.
Empadiance also provides cardiovascular benefits by lowering the risk of heart-related complications in diabetic patients with cardiovascular disease.
This medication is available in **10 mg** and **25 mg** strengths.
Empadiance 25 (Empagliflozin)
Dosage form: Tablet
Empadiance is indicated for:
• Control of blood glucose levels in adults with type 2 diabetes mellitus (as monotherapy or in combination with other antidiabetic agents such as Metformin or Insulin)
• Reduction of cardiovascular risk in diabetic patients with a history of heart disease
By promoting urinary glucose excretion, Empadiance helps lower blood glucose and supports weight and blood pressure control.
• Recommended dose: **10 mg once daily**.
The dose may be increased to **25 mg once daily** as directed by a physician.
• Can be taken in the morning, **with or without food**.
• Swallow the tablet whole with water — do not crush or chew.
• Maintain adequate hydration during treatment.
• Use under medical supervision, especially in patients with kidney or liver impairment.